Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celixir Limited
Alloy raises $75m in venture funding to further its mission of open-source antibody technology discovery. It also spins out portfolio companies, like ophthalmic-focused Broadwing.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.
Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.
- Other Names / Subsidiaries
- Cell Therapy Limited
- Cell Therapy, Ltd.